- Home
- CMTG vs REPL Comparison
CMTG vs REPL Comparison
Compare CMTG & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMTG
- REPL
- Stock Information
- Founded
- CMTG 2015
- REPL 2015
- Country
- CMTG United States
- REPL United States
- Employees
- CMTG N/A
- REPL N/A
- Industry
- CMTG Real Estate Investment Trusts
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- CMTG Real Estate
- REPL Health Care
- Exchange
- CMTG Nasdaq
- REPL Nasdaq
- Market Cap
- CMTG 881.0M
- REPL 851.0M
- IPO Year
- CMTG 2021
- REPL 2018
- Fundamental
- Price
- CMTG $3.75
- REPL $10.39
- Analyst Decision
- CMTG Hold
- REPL Strong Buy
- Analyst Count
- CMTG 7
- REPL 6
- Target Price
- CMTG $4.31
- REPL $20.00
- AVG Volume (30 Days)
- CMTG 2.1M
- REPL 682.9K
- Earning Date
- CMTG 05-05-2025
- REPL 05-15-2025
- Dividend Yield
- CMTG 9.36%
- REPL N/A
- EPS Growth
- CMTG N/A
- REPL N/A
- EPS
- CMTG N/A
- REPL N/A
- Revenue
- CMTG $9,029,000.00
- REPL N/A
- Revenue This Year
- CMTG $1,879.07
- REPL $31.16
- Revenue Next Year
- CMTG $2.19
- REPL N/A
- P/E Ratio
- CMTG N/A
- REPL N/A
- Revenue Growth
- CMTG N/A
- REPL N/A
- 52 Week Low
- CMTG $2.13
- REPL $4.92
- 52 Week High
- CMTG $9.81
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- CMTG 55.41
- REPL 32.87
- Support Level
- CMTG $3.88
- REPL $10.17
- Resistance Level
- CMTG $4.17
- REPL $10.78
- Average True Range (ATR)
- CMTG 0.28
- REPL 0.65
- MACD
- CMTG 0.03
- REPL -0.09
- Stochastic Oscillator
- CMTG 53.59
- REPL 10.71
About CMTG Claros Mortgage Trust Inc.
Claros Mortgage Trust Inc is a real estate investment trust. The company is focused mainly on originating senior and subordinate loans on transitional commercial real estate assets located in markets across the U.S.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.